[Erythropoietin: new perspectives in treating cardiac insufficiency?].
Erythropoietin, a hormone known to be a stimulator of erythropoiesis, is widely used in the treatment of anemia in patients with chronic renal failure. The latest experiments proved that it can also bring beneficial effects in patients with cardiovascular disease. It prevents cardiomyocyte apoptosis during myocardial infarction and can relieve disease symptoms in patients with congestive heart failure and anemia. Further experiments and clinical trials are necessary to investigate the pathophysiological mechanisms and clinical effects of this treatment.
Snopek
Grazyna
G
Kliniczny Oddział Kardiologii, Szpital Bielański w Warszawie. snopek@mp.pl
Popielarz-Grygalewicz
Agata
A
Dabrowski
Marek
M
D002316:Cardiotonic Agents / Q000627:therapeutic use*; D016207:Cytokines / Q000378:metabolism; D004921:Erythropoietin / Q000627:therapeutic use*; D006333:Heart Failure / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D006801:Humans; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy / Q000378:metabolism
D002316:Cardiotonic Agents; D016207:Cytokines; D004921:Erythropoietin